A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2022 Results published in the Journal of Bone and Mineral Research
26 Mar 2022 Results of retrospective analysis appling updated built in tissue thickness-adjusted TBS algorithm to investigate the long-term effect of denosumab on bone microarchitecture in FREEDOM and OLE in patients who completed the FREEDOM DXA substudy , presented at the 2022 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
01 Jan 2021 Results assessing effects of denosumab in the phase 3 FREEDOM study and combined all disutility-weighted fracture outcomes in phase 3 trials of osteoporosis, published in the Osteoporosis International

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com